1)日本アレルギー学会喘息ガイドライン専門部会(監):喘息予防・管理ガイドライン2021.協和企画,2021
2)Lange P, et al:Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 61:100-104, 2006 PMID 16443705
3)Richard B, et al:Inhaled corticosteroid therapy in adult ashma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med 199:1471-1477, 2019 PMID 30645143
4)Brode SK, et al:The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J 50:1700037, 2017 PMID 28931659
5)Nagase H, et al:Switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler improved small airway obstraction in elderly asthma patients. Allergology & Immunology 25:248-259, 2018
6)Barnes PJ:Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 19:182-191, 2002 PMID 11843317
7)Kerstjens HA, et al:Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 367:1198-1207, 2012 PMID 22938706
8)Fukumitsu K, et al:Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma. J Allergy Clin Immunol Pract 6:1613-1620.e2, 2018 PMID 29408386
9)Ichinose M, et al:Tiotropium 5microg via Respimat and 18microg via HandiHaler;Efficacy and safety in Japanese COPD patients. Respir Med 104:228-236, 2010 PMID 19969446
10)日本呼吸器学会 COPDガイドライン第6版作成委員会(編):COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン2022[第6版].メディカルレビュー社,2022
11)長瀬洋之:COPD治療におけるICSのポジショニング.呼吸器ジャーナル67:300-309, 2019
12)日本呼吸器学会 喘息とCOPDのオーバーラップ(Asthma and COPD Overlap:ACO)診断と治療の手引き第2版作成委員会(編):喘息とCOPDオーバラップ(Asthma and COPD Overlap:ACO)診断と治療の手引き 第2版 2023.メディカルレビュー社,2024